Emerging evidence has shown that COVID-19 survivors could suffer from persistent
symptoms. However, it remains unclear whether these symptoms persist over the longer …

Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Language models demonstrate both quantitative improvement and new qualitative
capabilities with increasing scale. Despite their potentially transformative impact, these new …

Background Findings from observational studies suggest that dietary patterns may offer
protective benefits against cognitive decline, but data from clinical trials are limited. The …

Background The impact of COVID-19 on physical and mental health and employment after
hospitalisation with acute disease is not well understood. The aim of this study was to …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Abstract The European Resuscitation Council (ERC) and the European Society of Intensive
Care Medicine (ESICM) have collaborated to produce these post-resuscitation care …

Importance Little is known about long-term sequelae of COVID-19. Objective To describe the
consequences at 4 months in patients hospitalized for COVID-19. Design, Setting, and …

Background Iron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …

Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …